CA-CONVIVA
4.11.2021 17:02:13 CET | Business Wire | Press release
Despite predictions of a ”pandemic peak,” streaming adoption continues to gain ground in almost every single region quarter after quarter, according to the Q3 2021 State of Streaming report from Conviva, the continuous measurement platform for streaming media. Streaming viewing time grew 21% worldwide in Q3 2021 as compared to the same quarter in 2020, led by Africa, Oceania and South America while North America, an established streaming market, held steady with the most modest growth of any region, up just 2%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005139/en/
“Streaming viewing has grown 266% over the past three years, completely transforming the entertainment, publishing and advertising industries,” said Keith Zubchevich, CEO, Conviva. “Topics like quality of experience, advertising measurement and social engagement are now top of mind and the publishers that effectively leverage opportunities to improve in these areas will not only lead the industry in subscribers and viewer satisfaction, but also revenue.”
The report also found streaming publishers investing heavily in video content on social media platforms in Q3 2021 – especially YouTube – in order to test new content and promote their catalog with viewers. In fact, streaming platforms increased their content output on YouTube by 97%, which resulted in an 8.4% increase in views and a 24% increase in engagement. Audiences for streaming platform accounts grew by 66% on YouTube in Q3 2021 as compared to Q3 2020.
Buffering Nearly Eliminated; Higher Quality = Higher Engagement
Q3 2021 marks the first quarter all regions experienced sub-1% buffering, with buffering seeing the largest improvements in more nascent regions like Africa, down 78% year over year. North America had the most modest gains over last year, with a 29% reduction in buffering, which was enough to maintain its position as the region with the least buffering at just 0.19%. Year over year, picture quality also made gains with bitrate improving in every region.
Higher quality delivered higher consumer engagement across the board. When buffering rates were less than 0.4%, viewers engaged for an average of 28.44 minutes in Q3, with that steadily declining with each incremental increase in buffering. Similarly, higher picture quality correlated with higher engagement as viewers averaged more than 20 minutes at bitrates above 3.5 Mbps in Q3 with engagement declining as bitrates dropped.
Big screen domination persisted
Despite seeing a slight decrease in share over Q3 of last year, big screens – which includes connected TV devices, smart TVs and gaming consoles – still accounted for almost three quarters (73%) of viewing time worldwide. Roku, Amazon Fire TV and Samsung TV made up the bulk of big screen viewing time globally with Roku again coming out on top with 31.1% share. Amazon Fire TV fell from 20% in Q3 2020 to 16.8% in Q3 2021, while Samsung gained nearly 3 percentage points over Q3 of last year going from 9.4% to 12.2% share of global viewing time. LG TV, Android TV, Apple TV and Chromecast also gained share over last year.
In every part of the world except Asia, big screens were the majority of viewership, particularly in North America with 82%. Mobile phones, desktops and tablets barely registered in North America at 8%, 6% and 4%, respectively.
Advertising continues advances in streaming
Streaming advertising made significant gains in Q3 2021. Ad attempts and ad impressions were up over 30% in Q3 2021, as compared to Q2 2021. Just 15% of ads in Q3 2021 were not delivered as intended, for a 23% decrease in missed ad opportunities quarter over quarter. Ad duration decreased by 3% from last quarter to 26 seconds, satisfying consumer requests for shorter ad breaks. Advertising quality was a mixed bag in Q3 2021, as ad buffering worsened by 22% and picture quality decreased 1% from last quarter.
Download the full report here .
Methodology
Conviva’s data is primarily collected using proprietary sensor technology with a global footprint of more than 500 million unique viewers watching 180 billion streams per year across nearly 4 billion applications streaming on devices. Embedded directly within streaming video applications, the sensor measures across content and ads to analyze nearly three trillion real-time transactions per day for its customers. In the State of Streaming report, the year-over-year data from Q3 2021 as compared to Q3 2020 was normalized based on Conviva’s customer base. The social media data consists of data from over 2800 accounts, over 21 million posts, and over 18 billion engagements across Facebook, Instagram, Twitter, and YouTube in Q3 2021.
About Conviva
Conviva is the census, continuous measurement and engagement platform for streaming media. Powered by our patented Stream Sensor™ and Stream ID™, our real-time platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005139/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
